Tag Archives: NIH

Rare Disease Day: Spotlight on Solidarity

Patients, policymakers and pharmaceutical companies are uniting around rare diseases on the rarest of calendar days, presaging a leap forward in health outcomes and business opportunities. Aligning humanistic objectives with business incentives is often the sine qua non of effective community activism. This year’s Rare Disease Day – hosted in the US by the National […]
Posted in Events, FDA, Global, healthcare, leadership, Patient Communication, patient education, social media, Strategy | Also tagged , , , , , , | Leave a comment

Government-Funded Research: Is It That Different?

In December 2011, the President’s Bioethics Commission released its “Moral Science: Protecting Participants in Human Subjects Research.” The report was ordered by President Obama following an October 2010 revelation that the US Public Health Service supported unethical research in Guatemala from 1946 to 1948 that involved intentionally exposing thousands of Guatemalans to sexually transmitted diseases […]
Posted in Guest Blog, R&D, Regulatory, Safety | Also tagged , , | Leave a comment

JP Morgan Healthcare Conference Marked by Uncertainty

2012 J.P. Morgan Healthcare Conference Marked by Uncertainty Audrey S. Erbes, Principal, Erbes & Associates, outlines the highlights of this week’s event in San Francisco. One of the few positive notes struck in this week’s 30th Annual J.P. Morgan Healthcare Conference (held in San Francisco) was the announcement by Kevin Willsey, J.P. Morgan’s co-head of […]
Posted in Guest Blog, healthcare, R&D, Strategy | Also tagged , , , | 2 Comments

New Coalition Takes on Neglected Tropical Diseases

A new coalition for sharing pharma IP takes aim at the increasing burden of neglected tropical diseases in the developing world. According to the World Health Organization, neglected tropical diseases affect more than one billion of the world’s poorest 2.7 billion people. Many of these diseases, which can cause blindness and other debilitating symptoms, have […]
Posted in Corporate Responsibility, IP | Also tagged , , , , | Leave a comment

NIH Director Speaks Out on the Institutes' New Remit

As the National Institutes for Health hits the headlines over its remit to help develop new medicines, Director Francis Collins talks to Pharm Exec about the new initiatives he sees as critical for innovation, industry and public health. Francis Collins devoted more than 15 years in the lab to deciphering the human genome. Ten years […]
Posted in FDA, Gene therapy, Guest Blog, healthcare, IP, leadership, R&D, Regulatory | Also tagged , , , , , | 1 Comment
  • Categories

  • Meta